(-0.41%) 5 460.48 points
(-0.12%) 39 119 points
(-0.71%) 17 733 points
(-0.34%) $81.46
(-3.13%) $2.60
(0.01%) $2 336.90
(0.61%) $29.44
(0.28%) $1 009.00
(-0.06%) $0.933
(0.45%) $10.68
(-0.05%) $0.791
(0.86%) $85.73
Live Chart Being Loaded With Signals
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health...
Stats | |
---|---|
Šios dienos apimtis | 108 389 |
Vidutinė apimtis | 149 783 |
Rinkos kapitalizacija | 1.70B |
EPS | $-0.120 ( Q1 | 2024-03-31 ) |
Kita pelno data | ( $-0.0600 ) 2024-08-27 |
Last Dividend | $0.0722 ( 2019-01-11 ) |
Next Dividend | $0 ( N/A ) |
P/E |
-17.78 (Sector) 49.64 (Industry) 35.32 |
ATR14 | $0.0160 (0.33%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2018-10-22 | Anderson Mark Monroe | Buy | 100 000 | Stock Option (right to buy) |
2018-10-22 | Anderson Mark Monroe | Buy | 0 | |
2018-08-13 | Smith Scott Clifford | Buy | 100 000 | Stock Option (right to buy) |
2018-08-13 | Smith Scott Clifford | Buy | 0 | |
2018-08-13 | Laffer Arthur B | Buy | 100 000 | Stock Option (right to buy) |
INSIDER POWER |
---|
0.00 |
Last 13 transactions |
Buy: 500 392 | Sell: 1 057 |
Tūris Koreliacija
Eaton Vance Ohio Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
HTZ | 0.916 |
ACHR-WT | 0.905 |
PNST | 0.904 |
CCG | 0.896 |
PPG | 0.89 |
GETY | 0.889 |
RHI | 0.888 |
AZUL | 0.888 |
CPRI | 0.886 |
YCL | 0.883 |
10 Labiausiai neigiamai susiję koreliacijos | |
---|---|
MRDB | -0.888 |
RRAC | -0.887 |
YCS | -0.883 |
TRIS | -0.873 |
TCOA | -0.871 |
TRTL | -0.87 |
TFPM | -0.868 |
APCA | -0.867 |
USDU | -0.865 |
MAIN | -0.864 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Eaton Vance Ohio Koreliacija - Valiuta/Žaliavos
Eaton Vance Ohio Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $781.43M |
Bruto pelnas: | $175.05M (22.40 %) |
EPS: | $-0.470 |
FY | 2023 |
Pajamos: | $781.43M |
Bruto pelnas: | $175.05M (22.40 %) |
EPS: | $-0.470 |
FY | 2022 |
Pajamos: | $751.45M |
Bruto pelnas: | $174.07M (23.16 %) |
EPS: | $-0.990 |
FY | 2021 |
Pajamos: | $618.03M |
Bruto pelnas: | $151.54M (24.52 %) |
EPS: | $0.650 |
Financial Reports:
No articles found.
Eaton Vance Ohio Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.0561 | 2001-01-05 |
Last Dividend | $0.0722 | 2019-01-11 |
Next Dividend | $0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 221 | -- |
Total Paid Out | $14.33 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.06 | -- |
Div. Sustainability Score | 2.23 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0.212 | -- |
Year | Amount | Yield |
---|---|---|
2001 | $0 | 0.00% |
2002 | $0 | 0.00% |
2003 | $0 | 0.00% |
2004 | $1.008 | 24.50% |
2005 | $1.024 | 55.70% |
2006 | $0.704 | 34.50% |
2007 | $0.650 | 153.20% |
2008 | $0.738 | 177.80% |
2009 | $0.814 | 150.70% |
2010 | $0.966 | 61.90% |
2011 | $0.857 | 41.40% |
2012 | $0.832 | 54.40% |
2013 | $0.793 | 45.30% |
2014 | $0.732 | 28.90% |
2015 | $0.732 | 32.70% |
2016 | $0.570 | 25.20% |
2017 | $0.576 | 14.20% |
2018 | $0.495 | 6.05% |
2019 | $0.0722 | 0.71% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Ex Date | Amount | Declaration Date | Record Date | Payment Date |
---|---|---|---|---|
11 Jan 2019 | $0.0722 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
12 Dec 2018 | $0.0451 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
10 Oct 2018 | $0.0451 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
13 Sep 2018 | $0.0451 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
10 Aug 2018 | $0.0451 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
11 Jul 2018 | $0.0451 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
08 Jun 2018 | $0.0451 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
10 May 2018 | $0.0451 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
11 Apr 2018 | $0.0451 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
09 Mar 2018 | $0.0451 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
09 Feb 2018 | $0.0451 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
11 Jan 2018 | $0.0451 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
08 Dec 2017 | $0.0451 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
10 Nov 2017 | $0.0451 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
11 Oct 2017 | $0.0451 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
08 Sep 2017 | $0.0451 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
09 Aug 2017 | $0.0451 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
11 Jul 2017 | $0.0451 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
08 Jun 2017 | $0.0509 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
09 May 2017 | $0.0509 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
ECC | Dividend Diamond | 2024-07-11 | Monthly | 11 | 14.91% | 9.72 |
BRW | Dividend Diamond | 2024-06-11 | Monthly | 33 | 9.41% | 9.26 |
VVR | Dividend Diamond | 2024-06-18 | Monthly | 27 | 8.85% | 9.19 |
FCT | Dividend Diamond | 2024-06-03 | Monthly | 21 | 8.33% | 9.14 |
PHK | Dividend Diamond | 2024-06-13 | Monthly | 22 | 9.07% | 9.13 |
SBR | Dividend Diamond | 2024-06-17 | Monthly | 38 | 9.57% | 9.10 |
XFLT | Dividend Diamond | 2024-06-17 | Monthly | 8 | 10.49% | 9.09 |
SRV | Dividend Royal | 2024-07-16 | Monthly | 18 | 10.61% | 9.04 |
FAM | Dividend Royal | 2024-06-03 | Monthly | 20 | 8.07% | 8.98 |
RA | Dividend Diamond | 2024-06-11 | Monthly | 9 | 10.10% | 8.93 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.117 | 1.500 | -2.34 | -3.50 | [0 - 0.5] |
returnOnAssetsTTM | -0.0411 | 1.200 | -1.369 | -1.642 | [0 - 0.3] |
returnOnEquityTTM | -0.0799 | 1.500 | -1.999 | -3.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 1.865 | 0.800 | 5.68 | 4.54 | [1 - 3] |
quickRatioTTM | 1.634 | 0.800 | 5.10 | 4.08 | [0.8 - 2.5] |
cashRatioTTM | 0.967 | 1.500 | 5.74 | 8.61 | [0.2 - 2] |
debtRatioTTM | 0.284 | -1.500 | 5.26 | -7.90 | [0 - 0.6] |
interestCoverageTTM | -8.44 | 1.000 | -4.24 | -4.24 | [3 - 30] |
operatingCashFlowPerShareTTM | -0.0782 | 2.00 | -0.0261 | -0.0521 | [0 - 30] |
freeCashFlowPerShareTTM | -1.274 | 2.00 | -0.637 | -1.274 | [0 - 20] |
debtEquityRatioTTM | 0.567 | -1.500 | 7.73 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.202 | 1.000 | 9.97 | 9.97 | [0.2 - 0.8] |
operatingProfitMarginTTM | -0.129 | 1.000 | -4.59 | -4.59 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -0.0221 | 1.000 | -1.234 | -1.234 | [0.2 - 2] |
assetTurnoverTTM | 0.352 | 0.800 | -0.989 | -0.791 | [0.5 - 2] |
Total Score | 2.23 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -8.76 | 1.000 | -0.986 | 0 | [1 - 100] |
returnOnEquityTTM | -0.0799 | 2.50 | -1.285 | -3.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -1.274 | 2.00 | -0.425 | -1.274 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -0.0782 | 2.00 | -0.0261 | -0.0521 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.614 | 1.500 | -7.43 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -0.0179 | 1.000 | -2.95 | 0 | [0.1 - 0.5] |
Total Score | -1.805 |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Eaton Vance Ohio
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.